0001493152-23-027352.txt : 20230809
0001493152-23-027352.hdr.sgml : 20230809
20230809161018
ACCESSION NUMBER: 0001493152-23-027352
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230807
FILED AS OF DATE: 20230809
DATE AS OF CHANGE: 20230809
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: COMMODORE CAPITAL LP
CENTRAL INDEX KEY: 0001831942
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37761
FILM NUMBER: 231155221
BUSINESS ADDRESS:
STREET 1: 444 MADISON AVENUE
STREET 2: 35TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
BUSINESS PHONE: 917-970-1730
MAIL ADDRESS:
STREET 1: 444 MADISON AVENUE
STREET 2: 35TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Vistagen Therapeutics, Inc.
CENTRAL INDEX KEY: 0001411685
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 205093315
STATE OF INCORPORATION: NV
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 343 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-577-3600
MAIL ADDRESS:
STREET 1: 343 ALLERTON AVENUE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: VistaGen Therapeutics, Inc.
DATE OF NAME CHANGE: 20110610
FORMER COMPANY:
FORMER CONFORMED NAME: Excaliber Enterprises, Ltd.
DATE OF NAME CHANGE: 20070906
4
1
ownership.xml
X0508
4
2023-08-07
0
0001411685
Vistagen Therapeutics, Inc.
VTGN
0001831942
COMMODORE CAPITAL LP
444 MADISON AVENUE
35TH FLOOR
NEW YORK
NY
10022
0
0
1
0
0
Common Stock
2023-08-07
4
P
0
775756
23.153
A
1575000
I
By Commodore Capital Master LP
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $16.00 to $25.00 per share, inclusive. The Reporting Person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.
The shares are held directly by Commodore Capital Master LP ("Commodore Master"). Commodore Capital LP ("Commodore Capital") is the investment manager to Commodore Master. Michael Kramarz and Robert Egen Atkinson are the managing partners of Commodore Capital and exercise investment and dispositive power over the securities held by Commodore Master. Each of Commodore Capital, Dr. Kramarz and Dr. Atkinson disclaim beneficial ownership of such securities, except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that Commodore Capital, Commodore Master, Dr. Kramarz and Dr. Atkinson or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
/s/ Michael Kramarz, Managing Partner
2023-08-09